Apolipoprotein C3 (APOC3) Antibody Pair
1495€ (5 × 96 tests)
Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.
935106861
info@markelab.com
name
Apolipoprotein C3 (APOC3) Antibody Pair
category
Antibody Pairs
provider
Abbexa
reference
abx370273
tested applications
ELISA
Description
Apolipoprotein C3 (APOC3) Antibody Pair for use in Sandwich ELISA assay development.
Documents del producto
Instrucciones
Data sheet
Product specifications
| Category | Antibody Pairs |
| Immunogen Target | Apolipoprotein C3 (APOC3) |
| Reactivity | Mouse |
| Assay Data | Detection Antibody Biotinilated |
| Assay Type | Sandwich |
| Recommended Dilution | Dilute the Capture Antibody 125-fold with Coating Buffer. Dilute the Biotin-Conjugated Detection Antibody 200-fold with Detection Antibody Diluent. Optimal dilutions/concentrations should be determined by the end user. |
| Size 1 | 5 × 96 tests |
| Size 2 | 10 × 96 tests |
| Form | Standard: Lyophilized--Liquid (Capture Antibody and Detection Antibody) Reconstitute the standard with Standard Diluent. The volume, and therefore standard concentration, should be determined by the end user. |
| Tested Applications | ELISA |
| Buffer | The Capture and Detection Antibody both contain 0.1% sodium azide. |
| Availability | Please enquire. |
| Storage | Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles. |
| Dry Ice | No |
| Alias | APOC3, APOCIII, HALP2, apolipoprotein C3, Apo-C3, ApoC-3,apo-CIII, and apolipoprotein C-III |
| Background | Antibody Pair for APOC3 |
| Status | RUO |
| Note | This antibody pair contains ( 5 x 96 det): Detection: 50 µg Capture: 200 µg Standard: 2 µg This product is for research use only. |
Descripción
APOC3 is a critical regulator of triglyceride-rich lipoprotein (TRL) metabolism, primarily associated with VLDL, HDL, and chylomicrons. APOC3 inhibits lipoprotein lipase (LPL) and hepatic uptake of remnant lipoproteins by interfering with the binding of TRLs to heparan sulfate proteoglycans (HSPG) and the low-density lipoprotein receptor (LDLR). Elevated APOC3 levels are strongly associated with hypertriglyceridemia, atherogenic dyslipidemia, and increased risk of cardiovascular disease. APOC3 expression is regulated by dietary factors, insulin, and nuclear receptors such as PPAR-alpha. Loss-of-function mutations in the APOC3 gene result in lower plasma triglycerides and reduced cardiovascular risk, highlighting its potential as a therapeutic target for lipid disorders. APOC3 also modulates inflammatory responses and has been implicated in non-alcoholic fatty liver disease (NAFLD), where elevated levels contribute to hepatic lipid accumulation. Pharmacological inhibitors of APOC3, such as antisense oligonucleotides, are being developed to lower plasma triglycerides and improve lipid profiles in hyperlipidemic patients.
Related Products
Human APOC3 (Apolipoprotein C-III) ELISA Kit
Ver Producto
Recombinant Human APOC3
Ver Producto